Umoja Biopharma stock

Umoja Biopharma Stock

HealthTech

Looking to sell Umoja Biopharma stock or options?

Founded: 2019Funding to Date: $374Mhttps://www.umoja-biopharma.com

Umoja Biopharma is a provider of advanced immunotherapies designed to revolutionize cancer treatment and enhance patient quality of life. The company's innovative cellular immunotherapy platform employs gene therapy to specifically target cancer cells. This platform can be delivered to any patient, with any type of tumor, at any given time. It works by directly, safely, and controllably attacking cancer, which empowers healthcare professionals to protect patients by generating and harnessing a robust immune response within the body.

Investors Include:

Presight Capital, Myeloma Investment Fund, RTW Investments, MPM BioImpact, Seattle Children's Hospital, Emerson Collective, Casdin Capital, WRF Capital, ARK Venture Fund, Cormorant Asset Management, Double Point Ventures, SoftBank Investment Advisers, University of Minnesota, CaaS Capital Management, Temasek Holdings, ARK Investment Management, Alexandria Venture Investments, K2 HealthVentures, Purdue Ventures, Qiming Venture Partners USA, Third Point Ventures, Leerink Partners, DCVC Bio, AbbVie Ventures.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more